Grants

NOTICE:

If you need access to the Grants (Private) page, please contact Angela Consorte.

This area of the VACS website is protected. Complete information can be found on the All Grants (Private) page.

Number Submitted Date Funding Source
U24-AA020794 (Justice) 09/01/16-08/31/21 NIAAA
Consortium to improve OutcoMes in hiv/Aids, Alcohol, Aging, & multi-Substance use (COMpAAAS)
Abstract Specific Aims Publications
U01-AA027090 (Justice) 09/01/16-08/31/21 NIAAA
Optimizing Treatment in HIV and HCV: ART, Alcohol and Polypharmacy
Abstract Specific Aims Publications
U01-AA020795 (Fiellin) 09/01/16-08/31/21 NIAAA
Financial Incentives, Randomization with Stepped Treatment (FIRST Trial) for Unhealthy Alcohol Use in HIV
Abstract Specific Aims Publications
U01-AA020799 (Braithwaite) 09/01/16-08/31/21 NIAAA
A simulation to inform intervention design for alcohol-using HIV-infected persons
Abstract Specific Aims Publications
U24-AA022001 (Brandt & Tate) 09/01/16-08/31/21 NIAAA
Resource in Informatics and Biostatistics (RIB)
Abstract Specific Aims Publications
R01 AA024706 (Braithwaite) 09/01/16-06/30/21 NIH, NIAAA

Should Screening and Treatment Strategies for Unhealthy Alcohol Use in HIV-infected Person Vary with Smoking, Depression and Substance Abuse?

The Yale site will be responsible for the statistical development and validation of data as well as participating in investigations on alcohol and substance abuse as they relate to HIV, smoking, and depression. They will assist in the development of the specific aims which intend to further determine the affect various screening and treatment strategies have amongst HIV-infected individuals who use alcohol.

Abstract (Project Reporter) Specific Aims Publications
R01-CA206465 (Justice/Lo Re) 07/01/16 – 05/31/21 NIH, NCI

(PQ4) HIV and Aging Mechanisms for Hepatocellular Cancer

Determine if cumulative exposure to hepatotoxic antiretroviral drugs (ARVs) or polypharmacy differentially increase risk of HCC or alter HCC histology. Among HIV+ patients on ART, determine if cumulative exposure to immune activation and dysfunction and HIV-1 RNA increase risk of HCC after adjustment for known risk factors (HCV, HBV, alcohol, obesity, and diabetes) or alter HCC histology. Among HIV+ compared with uninfected, determine if obesity or diabetes have a differential association with risk of HCC (after controlling for known risk factors for HCC) or alter HCC histology.

Abstract (Project Reporter) Specific Aims Publications
R01-CA173754 (Crothers/Braithwaite/Wisnivesky) 04/10/13-03/31/18 NIH, NCI

Benefits and Harms of Lung Cancer Screening in HIV Infection

The goals of this project are to determine if screening for lung cancer could result in a mortality benefit for HIV-infected persons, given the increased risk of lung cancer in this population, although competing risks for mortality and the likelihood of false positive screening exams may be increased. We propose a mathematical modeling approach to synthesize the overall benefits and harms of lung cancer screening in the context of HIV.

Abstract (Project Reporter) Specific Aims Publications
R01-HL125032-01 (Freiberg) 08/27/14 – 06/30/18 NIH, NHLBI

Immune Function and the Risk of CVD among HIV Infected and Uninfected Veterans

The overall hypothesis is that alterations in immune cell function are associated with incident CVD and will explain the excess risk of CVD among HIV+ people compared to HIV- people.

Abstract (Project Reporter) Specific Aims Publications
R01-AA023733 (Fiellin/Tate) 02/15/15-01/31/18 NIH, NIAAA

Safety and Comparative Effectiveness of New Medications for Unhealthy Alcohol Use in HIV

Through the use of propensity score analyses, this study hopes to determine incident adverse clinical outcomes associated with varenicline, gabapentin and topiramante as well as the effect these 3 medications have on AUDIT-C score and CD4, viral load and VACS-Index.

Abstract (Project Reporter) Specific Aims Publications
VA-ORH (Justice/Lo Re) 10/01/15–09/30/1 VA, ORH

Rural-Urban Disparities in Hepatitis C virus (HCV) Testing and Direct Acting Antiretroviral Treatments

Describe HCV testing and screening by rural vs. urban Veteran residence, and facility rurality, in both unadjusted analyses and analyses adjusted for race, age, ethnicity and prevalence of HCV. Describe dissemination of DAA treatment in unadjusted analyses and analyses adjusted for race, age, ethnicity ,prevalence of HCV, and FIB 4 level (estimated risk of liver fibrosis).

Abstract Specific Aims
i01 BX003341 (Federman/Justice/Kranzler) 10/01/16 – 09/30/17 VA, BLRD

Genetic Vulnerability for Sustained Multi-Substance Use in MVP

The goals of this study are to define and identify highly valid, longitudinal heavy substance use phenotypes in the MVP using VACS-validated algorithms; conduct GWAS for sustained heavy use of tobacco, alcohol and opioids and dual/multi-substance use; and to replicate the GWAS findings.

Abstract Specific Aims Publications
R01-HL129586 (Hsue) 09/15/16-06/30/20 NIH, NHLBI

Protein Biomarkers for CVD Prediction in HIV-infected and Uninfected Veterans

The Yale staff will be responsible for arranging the transfer of VACS Banked Samples from the MAVERIC Laboratories in Boston, MA to the proteomics laboratories in Denver, CO for proteomic analysis. They will pull and clean matching phenotypic data from the VACS database. They will then merge and de-identify the proteomic and phenotypic data, producing a single combined database for analysis by the UCSF, Vanderbilt and Yale investigatory team. They will ensure all work is carried out in accordance with study IRB protocols.

Specific Aims Publications
Number Period Funding Source
Mechanism (PI) MM/DD/YY-MM/DD/YY Institute

Project Title

Summary of grant (Paragraph)

Abstract (Project Reporter) Specific Aims Publications
Mechanism (PI) MM/DD/YY-MM/DD/YY Institute

Project Title

Summary of grant (Paragraph)

Abstract (Project Reporter) Specific Aims Publications
Number Period Funding Source
R01-DA035616 (Fiellin) 04/01/13-02/28/17 NIH, NIDA

Using the VACS Index to Track Health Outcomes Associated with Changes in Drug use

Summary of grant (Paragraph)

Abstract (Project Reporter) Specific Aims Publications
U24-AA020794 (Justice) 09/01/11-08/31/16 NIAAA

Consortium to improve OutcoMes in hiv/Aids, Alcohol, Aging, & multimorbidity Substance use

The goal of this consortium U24 grant is to provide new knowlege to improve the health care of HIV infected persons harmed by alcohol and related conditions (multisubstance use, HCV, and depression) through insights from observation, intervention, and simulation modeling. (Runs in conjunction with 1U01AA020790)

Abstract (Project Reporter) Specific Aims Publications
U01-AA020790 (Justice) 09/01/11-08/31/16 NIAAA

Alcohol and Multisubstance Use in the Veterans Aging Cohort Study

The goal of this consortium U01 grant is to provide new knowlege to improve the health care of HIV infected persons harmed by alcohol and related conditions (multisubstance use, HCV, and depression) through insights from observation, intervention, and simulation modeling. (Runs in conjunction with U24AA020794)

Abstract (Project Reporter) Specific Aims Publications
U01-AA020795 (Fiellin) 09/01/11-08/31/16 NIAAA
Consortium to improve OutcoMes in hiv/Aids, Alcohol, Aging, & multimorbidity Substance use Intervention
Abstract (Project Reporter) Specific Aims Publications
U01-AA0207099 (Braithwaite) 09/01/11-08/31/16 NIAAA
Consortium to improve OutcoMes in hiv/Aids, Alcohol, Aging, & multimorbidity Substance use OR Model Sci
Abstract (Project Reporter) Specific Aims Publications

Justice NIAAA U10-AA013566 VACS NCBI